Publications

Title

Author

Year

Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (P...

NATUKUNDA, A; NKURUNUNGI, G; ZIRIMENYA, L; Nassuuna, J; Oduru, G; Amongin, R; Kabuubi, PN; Mutebe, A; Onen, C; Amongi, S; Nakazibwe, E; Akello, F; Kiwanuka, S; Kiwudhu, F; Sewankambo, M; Nsubuga, D; Kizindo, R; STAEDKE, SG; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040427.

Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA).

Tanner, R; ZELMER, A; PAINTER, H; Stylianou, E; Pinpathomrat, N; Harrington-Kandt, R; Biffar, L; Brennan, M; McShane, H; FLETCHER, H;

2021

bioRxiv (2021). 10.1101/2021.02.14.431105.

'We had to manage what we had on hand, in whatever way we could': adaptive responses in policy for decentralized drug-resistant tuberculosis care in South Africa.

Kielmann, K; Dickson-Hall, L; Jassat, W; Le Roux, S; Moshabela, M; Cox, H; GRANT, AD; Loveday, M; Hill, J; Nicol, MP; Mlisana, K; Black, J;

2021

Health policy and planning, (2021).36 3 10.1093/heapol/czaa147.

Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?.

DOCKRELL, HM; BUTKEVICIUTE, E;

2021

Vaccine, (2021).40 11 10.1016/j.vaccine.2021.01.068.

Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda.

Reza, TF; Nalugwa, T; Nantale, M; Adams, K; FIELDING, K; Nakaweesa, A; Oyuku, D; Nabwire, S; Musinguzi, J; Ojok, C; Babirye, D; Ackerman, SL; Handley, MA; Kityamuwesi, A; Dowdy, DW; MOORE, DA J; Davis, JL; Turyahabwe, S; Katamba, A; Cattamanchi, A;

2021

Contemporary clinical trials communications, (2021).22, 10.1016/j.conctc.2021.100707.

Mitigating the impact of COVID-19 on tuberculosis and HIV services: A cross-sectional survey of 669 health professionals in 64 low and middle-income countries.

KHAN, MS; REGO, S; Rajal, JB; BOND, V; Fatima, RK; Isani, AK; SUTHERLAND, J; KRANZER, K;

2021

PLoS One, (2021).16 2 10.1371/journal.pone.0244936.

P162 Developing a tuberculosis patient cost survey adapted to the UK setting: recommendations from a national multi-sectoral workshop.

Green, RJ; Anderson, S; Squire, SB; Tomeny, E; Siqueira, N; SWEENEY, S; Zenner, D; Mandelbaum, M; Wingfield, T;

2021

TB or not TB, is that the question? (2021). 10.1136/thorax-2020-btsabstracts.307.

Re-sensitization of Mycobacterium smegmatis to Rifampicin Using CRISPR Interference Demonstrates Its Utility for the Study of Non-essential Drug Resistance Traits.

Faulkner, V; Cox, AA; Goh, S; Van Bohemen, A; Gibson, AJ; Liebster, O; WREN, BW; WILLCOCKS, S; Kendall, SL;

2021

Frontiers in microbiology, (2021).11, 10.3389/fmicb.2020.619427.

Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.

Scriba, TJ; Fiore-Gartland, A; Penn-Nicholson, A; Mulenga, H; Kimbung Mbandi, S; Borate, B; Mendelsohn, SC; Hadley, K; Hikuam, C; Kaskar, M; Musvosvi, M; Bilek, N; Self, S; SUMNER, T; WHITE, RG; Erasmus, M; Jaxa, L; Raphela, R; Innes, C; Brumskine, W; Hiemstra, A; Malherbe, ST; Hassan-Moosa, R; Tameris, M; Walzl, G; ... CORTIS-01 Study Team,

2021

The Lancet. Infectious diseases, (2021).21 3 10.1016/S1473-3099(20)30914-2.

Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.

BENEST, J; RHODES, S; QUAIFE, M; Evans, TG; WHITE, RG;

2021

Vaccines, (2021).9 2 10.3390/vaccines9020078.